No interruption of lactation is needed after (11)C-WAY 100635 or (11)C-raclopride PET.
Moses-Kolko
Eydie L
EL
Meltzer
Carolyn Cidis
CC
Helsel
Joseph C
JC
Sheetz
Michael
M
Mathis
Chestera
C
Ruszkiewicz
James
J
Bogen
Debra
D
Confer
Andrea L
AL
Wisner
Katherine L
KL
D000328:Adult; D005260:Female; D006801:Humans; D007774:Lactation / Q000378:metabolism*; D008895:Milk, Human / Q000737:chemistry*; D010879:Piperazines / Q000032:analysis / Q000493:pharmacokinetics*; D049268:Positron-Emission Tomography / Q000379:methods; D011725:Pyridines / Q000032:analysis / Q000493:pharmacokinetics*; D020891:Raclopride / Q000032:analysis / Q000493:pharmacokinetics*; D011829:Radiation Dosage; D011874:Radiometry / Q000379:methods*; D019275:Radiopharmaceuticals / Q000032:analysis / Q000493:pharmacokinetics; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors
D010879:Piperazines; D011725:Pyridines; D019275:Radiopharmaceuticals; D020891:Raclopride; C090413:N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide